XML 58 R46.htm IDEA: XBRL DOCUMENT v3.6.0.2
Agreements - Lily (Details)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 61 Months Ended 72 Months Ended
Dec. 31, 2014
USD ($)
Dec. 31, 2013
USD ($)
Aug. 31, 2013
USD ($)
Dec. 31, 2016
USD ($)
Sep. 30, 2016
USD ($)
Jun. 30, 2016
USD ($)
Mar. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Sep. 30, 2015
USD ($)
Jun. 30, 2015
USD ($)
Mar. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Sep. 30, 2014
USD ($)
Dec. 31, 2016
USD ($)
item
Dec. 31, 2015
USD ($)
Jun. 30, 2016
USD ($)
Jun. 30, 2015
USD ($)
Jun. 30, 2014
USD ($)
Dec. 31, 2011
USD ($)
item
Dec. 31, 2016
USD ($)
Dec. 31, 2016
USD ($)
Collaborative Agreements disclosures                                          
Amount of arrangement consideration included in license and milestone fees       $ 5,076,000 $ 76,000 $ 76,000 $ 10,077,000 $ 10,692,000 $ 6,070,000 $ 5,086,000 $ 5,078,000 $ 41,417,000 $ 6,234,000 $ 5,152,000 $ 16,762,000 $ 26,915,000 $ 57,815,000 $ 39,455,000      
Costs related to the research and development services       $ 33,657,000 $ 32,909,000 38,652,000 $ 36,094,000 $ 38,199,000 $ 35,132,000 $ 30,437,000 $ 25,666,000 $ 27,647,000 $ 28,018,000 $ 66,566,000 $ 73,331,000 148,077,000 111,768,000 106,958,000      
Lilly                                          
Collaborative Agreements disclosures                                          
Number of development and commercialization licenses taken | item                           3         3    
Payments received under collaboration agreement $ 2,000,000 $ 2,000,000                                 $ 20,000,000 $ 28,200,000 $ 23,500,000
License exercise fee, per license                                     2,000,000    
Potential milestone payments                                     199,000,000    
Potential milestone payments with no exercise fee                                     $ 200,500,000    
Estimated utilization period after commercialization                                     10 years    
Discount rate (as a percent)                                     16.00%    
Amount of arrangement consideration included in license and milestone fees     $ 7,800,000                           15,600,000        
Estimated term of development and commercialization license                                     25 years    
Costs related to the research and development services                           $ 46,000   182,000 499,000 1,200,000      
Costs related to clinical materials sold                           $ 0   1,100,000 $ 1,100,000 $ 26,000      
Lilly | Exercise fee                                          
Collaborative Agreements disclosures                                          
Number of development and commercialization licenses taken | item                                     2    
Lilly | No exercise fee                                          
Collaborative Agreements disclosures                                          
Number of development and commercialization licenses taken | item                                     1    
Lilly | Development milestones                                          
Collaborative Agreements disclosures                                          
Potential milestone payments                                     $ 29,000,000    
Potential milestone payments with no exercise fee                                     30,500,000    
Lilly | Phase I clinical trial                                          
Collaborative Agreements disclosures                                          
Potential milestone payments           5,000,000                   5,000,000          
Amount of arrangement consideration included in license and milestone fees                               5,000,000          
Lilly | Phase II clinical trial                                          
Collaborative Agreements disclosures                                          
Potential milestone payments           $ 9,000,000                   $ 9,000,000          
Lilly | Future Technological Improvements                                          
Collaborative Agreements disclosures                                          
Payments received under collaboration agreement                                         600,000
Lilly | Research Services                                          
Collaborative Agreements disclosures                                          
Payments received under collaboration agreement                                         3,300,000
Lilly | Regulatory milestones                                          
Collaborative Agreements disclosures                                          
Potential milestone payments                                     70,000,000    
Lilly | Sales milestones                                          
Collaborative Agreements disclosures                                          
Payments received under collaboration agreement                                         $ 800,000
Potential milestone payments                                     $ 100,000,000